When: Post-Q3 beat-and-raise confirmed; 200 SMA reclaim in progress (2 of 3 confirmations: beat, guide up, structural reclaim)

Then: Add to 75% at $440-455 pullback into reclaimed 200 SMA

When: Sustained close above $480 breakout level

Then: Add final 25% at $480-495 reclaim zone

When: Q3 miss validated; price stabilized at $350-370 or $329 retest + new base

Then: Re-engage at $355-365 with positive momentum divergence after Q4 print confirms or rejects

Wait for either a breakout above $445 with a closing print or a pullback to $398-$405 with a reversal candle before initiating; if forced to act before Q3, reduce position size to 25-30% of target weight to limit portfolio risk to 0.5%; do not scale up before earnings—scale up after.

• 200 SMA sits at $444.19 with price at $415.41, twenty-eight dollars below the long-term trend line; death cross remains intact with 50 SMA below 200 SMA
• Technical report itself recommends HOLD with triggers at $445 (breakout) or $398 (pullback)—current price at $405 is in the "dead zone" between them
• Revenue grew 18.5% YoY in Q2'26; 70% recurring revenue base is real but 30% IS capital equipment is sensitive to long-end yields and hospital capex deferrals
• Stock fell from $604 to $329 in seven months during prior macro-driven demand deferral period; environment for capital equipment may not improve before Q3 print
• Forward EPS estimate of $12.11 implies forward PEG of 0.87; however, if Q3 disappoints and EPS revised to $11, forward P/E rises from 34.3 to 36.8
• Receivables grew 27% YoY against revenue growth of 18.5%, stretching days-sales-outstanding—potential early demand softness signal
• Inventory up 22% YoY against revenue up 18.5%, rising inventory days; surgical platform obsolescence risk makes this a quality-of-earnings flag
• ATR is $11.36; proposed stop at $383 is ~2 ATR but inadequate given beta of 1.46 and stock's history of 40-50% directional moves
• Absence of sentiment means no one paying attention—not bullish positioning, but also no one rushing in to provide a bid
• Two of the largest medical device companies (Hugo, Ottava) are actively competing; competitive pressure shows up gradually as decelerating procedure growth, margin pressure, then visible share loss

→ vs aggressive: The ATR compression and rising MACD describe a counter-trend rally within a confirmed bearish regime, not a trend reversal; treating the bounce as the new trend contradicts standard technical definitions with the death cross intact and 50 SMA below 200 SMA

→ vs aggressive: Forward PEG of 0.87 is only compelling if forward EPS of $12.11 holds; trailing P/E of 47.6x is what the market actually paid, and forward estimates are the stale data point most likely to be revised in the next 30 days

→ vs aggressive: Inventory and receivables growth outpacing revenue (22% and 27% vs 18.5%) is a quality-of-earnings flag, not just strategic staging; rising DSO can signal collections difficulty and demand softness

→ vs aggressive: Absent sentiment means no edge from the sentiment channel either way—it's not a positive, just neutral with low confidence; quiet is not the same as constructive

→ vs aggressive: The 5.4% stop is calibrated for a normal-volatility stock; with beta of 1.46 and a stock that moved $275 in seven months, the stop would gap through on a Q3 miss, making it appear tight on a chart but functionally inadequate

Initiate 40% of target weight at $405 with closing-price stop at $383; scale to 75% on post-Q3 close above $445 with confirmed momentum; reserve final 25% for pullback OR breakout above $480; consider put spread around earnings for mechanical risk definition; evaluate within broader portfolio healthcare/growth exposure context

• 40% initial position captures breakout dynamics without full gap-through-stop exposure
• Post-Q3 scaling: 75% on clean close above $445, final 25% on pullback or sustained breakout above $480
• Closing-price stop at $383 protects against low-liquidity overnight gaps (intraday stop fails with beta 1.46)
• Trailing 47.6x P/E is the real valuation metric—forward $12.11 EPS is a forecast that could be revised lower
• Q2'26 revenue growth of 18.5% YoY demonstrates ISRG can grow through the hawkish regime
• Both receivables (up 27% YoY) and inventory (up 22% YoY) growing faster than revenue is a quality-of-earnings flag worth scrutinizing
• MACD histogram expanding, RSI walking from 35 to 63 without divergence, 10 EMA stair-stepping higher confirms momentum
• Macro headwind is a known dampener, not a growing threat—the market has partially priced it in already
• Pair trade: Long ISRG / Short SYK or MDT to neutralize macro sensitivity while expressing fundamental view
• Competitive threat from Hugo/Ottava not yet visible in margins or revenue data—no evidence of disruption yet

→ vs aggressive: Forward EPS at $12.11 is a forecast, not hard data—if Q3 misses modestly, forward EPS falls to ~$11 and PEG ratio rises from 0.87 toward 1.0, weakening the valuation argument significantly

→ vs aggressive: Gap risk is real: with beta 1.46, earnings days away, and history of 40-50% moves, the $383 stop may not execute cleanly on a gap-down open; a closing-price stop is necessary

→ vs aggressive: Buying 'around' a quality-of-earnings flag (receivables up 27%, inventory up 22% vs revenue up 18.5%) means you still own the flag if it turns red at Q3 print

→ vs conservative: Competitive threat argument uses theory to dismiss specific evidence—no margin pressure, accelerating revenue, expanding gross margins, and Q2'26 moat validation contradict the disruption thesis

→ vs conservative: Position sizing compromise (50-60% down to 25-30%) doesn't actually reduce binary gap risk; halving position size just means smaller losses, not eliminated risk—the conservative analyst's position sizing doesn't address the core issue

→ vs conservative: Macro argument that 'environment doesn't get better' is true but incomplete—the operative question is whether conditions will GET WORSE, and if the market has already priced in the hawkish Fed, the headwind is already reflected, not growing